Synthetic biology and therapeutic strategies for the degenerating brain

Synthetic biology is an emerging engineering discipline that attempts to design and rewire biological components, so as to achieve new functions in a robust and predictable manner. The new tools and strategies provided by synthetic biology have the potential to improve therapeutics for neurodegenerative diseases. In particular, synthetic biology will help design small molecules, proteins, gene networks, and vectors to target disease‐related genes. Ultimately, new intelligent delivery systems will provide targeted and sustained therapeutic benefits. New treatments will arise from combining ‘protect and repair’ strategies: the use of drug treatments, the promotion of neurotrophic factor synthesis, and gene targeting. Going beyond RNAi and artificial transcription factors, site‐specific genome modification is likely to play an increasing role, especially with newly available gene editing tools such as CRISPR/Cas9 systems. Taken together, these advances will help develop safe and long‐term therapies for many brain diseases in human patients.

[1]  J. Salamone,et al.  The Mysterious Motivational Functions of Mesolimbic Dopamine , 2012, Neuron.

[2]  A. Björklund,et al.  Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. , 2014, JAMA neurology.

[3]  G. Lutz,et al.  Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy , 2009, The Journal of Neuroscience.

[4]  Amy L. Byers,et al.  Depression and risk of developing dementia , 2011, Nature Reviews Neurology.

[5]  Martin Fussenegger,et al.  An engineered mammalian band-pass network , 2010, Nucleic acids research.

[6]  Jens Boch,et al.  Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors , 2010, Proceedings of the National Academy of Sciences.

[7]  M. Isalan,et al.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice , 2012, Proceedings of the National Academy of Sciences.

[8]  J. F. Wright,et al.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  S. G. Stolberg.  The biotech death of Jesse Gelsinger. , 1999, The New York times magazine.

[10]  D. Houitte,et al.  Restricted transgene expression in the brain with cell-type specific neuronal promoters. , 2012, Human gene therapy methods.

[11]  M. Ehrlich,et al.  Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design , 2011, Gene Therapy.

[12]  Dana Carroll,et al.  Stimulation of Homologous Recombination through Targeted Cleavage by Chimeric Nucleases , 2001, Molecular and Cellular Biology.

[13]  P. Starr,et al.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. , 2012, Human gene therapy.

[14]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[15]  B. Davidson,et al.  Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response. , 2008, Human gene therapy.

[16]  Martin Fussenegger,et al.  Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome , 2012, Proceedings of the National Academy of Sciences.

[17]  Timothy S. Ham,et al.  Production of the antimalarial drug precursor artemisinic acid in engineered yeast , 2006, Nature.

[18]  R. Bakay,et al.  Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial , 2011, Lancet Neurology.

[19]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[20]  H. Okano,et al.  Common marmoset as a new model animal for neuroscience research and genome editing technology , 2014, Development, growth & differentiation.

[21]  G. Braunstein,et al.  Global clinical response in Cushing’s syndrome patients treated with mifepristone , 2014, Clinical endocrinology.

[22]  J. I. Izpisúa Belmonte,et al.  A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells* , 2013, The Journal of Biological Chemistry.

[23]  Sheng Huang,et al.  TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain , 2010, Nucleic Acids Res..

[24]  D. Burn,et al.  Parkinson's disease: The quintessential neuropsychiatric disorder , 2011, Movement disorders : official journal of the Movement Disorder Society.

[25]  Megan L. McCain,et al.  A tissue-engineered jellyfish with biomimetic propulsion , 2012, Nature Biotechnology.

[26]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[27]  Chris Bailey-Kellogg,et al.  Open Access Methodology Article Optimization Algorithms for Functional Deimmunization of Therapeutic Proteins , 2022 .

[28]  N. Zhang,et al.  One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering. , 2014, The international journal of biochemistry & cell biology.

[29]  M. Menéndez-González.  The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice , 2014, Front. Aging Neurosci..

[30]  Brian L. Gilmore,et al.  Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi , 2008, Proceedings of the National Academy of Sciences.

[31]  E. Shapiro,et al.  Detection of multiple disease indicators by an autonomous biomolecular computer. , 2011, Nano letters.

[32]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[33]  Randall J. Platt,et al.  Optical Control of Mammalian Endogenous Transcription and Epigenetic States , 2013, Nature.

[34]  N. Bresolin,et al.  Antisense Oligonucleotide Therapy for the Treatment of C9ORF72 ALS/FTD Diseases , 2014, Molecular Neurobiology.

[35]  Joshy Jacob,et al.  The Hybrid Cytomegalovirus Enhancer/Chicken β-Actin Promoter along with Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances the Protective Efficacy of DNA Vaccines1 , 2004, The Journal of Immunology.

[36]  Hui Zhao,et al.  Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors , 2014, Nucleic acids research.

[37]  K. Fernandes,et al.  Aging and neurogenesis in the adult forebrain: what we have learned and where we should go from here , 2013, The European journal of neuroscience.

[38]  R. Barker,et al.  Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial , 2014, The Lancet.

[39]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[40]  Yan Huang,et al.  Induction of angiogenesis in a mouse model using engineered transcription factors , 2002, Nature Medicine.

[41]  N. Toni,et al.  An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ , 2012, The Journal of Neuroscience.

[42]  Michael Söderman,et al.  Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. , 2012, Journal of neurosurgery.

[43]  R. Myers,et al.  Identification and functional analysis of human transcriptional promoters. , 2003, Genome research.

[44]  N. Nukina,et al.  Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein , 2010, Nature Biotechnology.

[45]  Charles A. Gersbach,et al.  Light-Inducible Spatiotemporal Control of Gene Activation by Customizable Zinc Finger Transcription Factors , 2012, Journal of the American Chemical Society.

[46]  V. Lee,et al.  Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases , 2014, Nature Medicine.

[47]  S. Basu,et al.  A synthetic multicellular system for programmed pattern formation , 2005, Nature.

[48]  C. von Kalle,et al.  Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.

[49]  Nazanin Mirzaei,et al.  Dose-dependent neuroprotection of VEGF₁₆₅ in Huntington's disease striatum. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[50]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[51]  U. A. Ørom,et al.  Molecular mechanisms of long ncRNAs in neurological disorders , 2014, Front. Genet..

[52]  J. MulcahyPádraig,et al.  Gene Therapy: A Promising Approach to Treating Spinal Muscular Atrophy , 2014 .

[53]  Yoshiro Shiba,et al.  Lesions of Ventrolateral Prefrontal or Anterior Orbitofrontal Cortex in Primates Heighten Negative Emotion , 2012, Biological Psychiatry.

[54]  Erin L. Doyle,et al.  Targeting DNA Double-Strand Breaks with TAL Effector Nucleases , 2010, Genetics.

[55]  D. Emerich,et al.  Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer , 2011, Gene Therapy.

[56]  W. Seeley,et al.  Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells , 2013, Stem cell reports.

[57]  G. Logroscino,et al.  Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? , 2014, Current opinion in psychiatry.

[58]  S. Kügler,et al.  Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain , 2013, Molecular therapy. Nucleic acids.

[59]  M. Häusser,et al.  Targeting neurons and photons for optogenetics , 2013, Nature Neuroscience.

[60]  C. Mussolino,et al.  Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa , 2011, EMBO molecular medicine.

[61]  S. Sidhu,et al.  Synthetic antibody technologies. , 2014, Current opinion in structural biology.

[62]  Steven J. M. Jones,et al.  A regulatory toolbox of MiniPromoters to drive selective expression in the brain , 2010, Proceedings of the National Academy of Sciences.

[63]  Luis Diambra,et al.  Genetically Encoded Sender–Receiver System in 3D Mammalian Cell Culture , 2013, ACS synthetic biology.

[64]  Christopher A. Voigt,et al.  Genetic programs constructed from layered logic gates in single cells , 2012, Nature.

[65]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[66]  J. Os,et al.  The size and burden of mental disorders and other disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.

[67]  Wei-Ting Hwang,et al.  Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. , 2014, The New England journal of medicine.

[68]  K. Deisseroth,et al.  Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy , 2012, Science Translational Medicine.

[69]  Stolberg Sg.  The biotech death of Jesse Gelsinger. , 1999 .

[70]  N. Bresolin,et al.  Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. , 2014, Clinical therapeutics.

[71]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[72]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[73]  A. Lang,et al.  Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients , 2013, Neurology.

[74]  S. Niclou,et al.  Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system , 2010, BMC Neuroscience.

[75]  Sanjay Pandey.  Parkinson's disease: recent advances. , 2012, The Journal of the Association of Physicians of India.

[76]  Farshid Guilak,et al.  Synergistic and tunable human gene activation by combinations of synthetic transcription factors , 2013, Nature Methods.

[77]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[78]  John C. Chaput,et al.  Synthetic Genetic Polymers Capable of Heredity and Evolution , 2012, Science.

[79]  Gorka Orive,et al.  Encapsulated cell therapy for neurodegenerative diseases: from promise to product. , 2014, Advanced drug delivery reviews.

[80]  Martin Fussenegger,et al.  Reward-based hypertension control by a synthetic brain–dopamine interface , 2013, Proceedings of the National Academy of Sciences.

[81]  Jeffrey C. Miller,et al.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.

[82]  Lei Wang,et al.  Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos , 2014, Cell.

[83]  R. Daniel,et al.  Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy , 2012, Gene Therapy.

[84]  A. Pastore,et al.  Kaleidoscopic protein–protein interactions in the life and death of ataxin-1: new strategies against protein aggregation , 2014, Trends in Neurosciences.

[85]  K. Bankiewicz,et al.  An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons , 2011, Brain Research.

[86]  Y. Doyon,et al.  Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme , 2012, Genome research.

[87]  Kristy M. Hawkins,et al.  Synthetic biology: evolution or revolution? A co-founder's perspective. , 2013, Current opinion in chemical biology.

[88]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[89]  Markus Wieland,et al.  Programmable single-cell mammalian biocomputers , 2012, Nature.

[90]  F. Gage,et al.  Modeling brain disease in a dish: really? , 2012, Cell stem cell.

[91]  Yan Ao,et al.  Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington's disease model mice , 2014, Nature Neuroscience.

[92]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[93]  Morgan L. Maeder,et al.  CRISPR RNA-guided activation of endogenous human genes , 2013, Nature Methods.

[94]  W. Ge,et al.  TALEN-mediated gene mutagenesis in rhesus and cynomolgus monkeys. , 2014, Cell stem cell.

[95]  L. Smeeth,et al.  Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[96]  Elo Leung,et al.  A TALE nuclease architecture for efficient genome editing , 2011, Nature Biotechnology.

[97]  L. Nissim,et al.  A tunable dual-promoter integrator for targeting of cancer cells , 2010, Molecular systems biology.

[98]  C. Taghibiglou,et al.  Novel Central Nervous System Drug Delivery Systems , 2014, Chemical biology & drug design.

[99]  E. Basner-Tschakarjan,et al.  Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors , 2014, Front. Immunol..

[100]  Y. Hua,et al.  Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. , 2008, American journal of human genetics.

[101]  Mark Isalan,et al.  p53 Gene Repair with Zinc Finger Nucleases Optimised by Yeast 1-Hybrid and Validated by Solexa Sequencing , 2011, PloS one.

[102]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[103]  Lauren K. Fong,et al.  An Engineered Zinc Finger Protein Activator of the Endogenous Glial Cell Line-Derived Neurotrophic Factor Gene Provides Functional Neuroprotection in a Rat Model of Parkinson's Disease , 2010, The Journal of Neuroscience.

[104]  E. Androphy,et al.  Splicing of a Critical Exon of Human Survival Motor Neuron Is Regulated by a Unique Silencer Element Located in the Last Intron , 2006, Molecular and Cellular Biology.

[105]  Javier Macía,et al.  Distributed biological computation with multicellular engineered networks , 2011, Nature.

[106]  P. Pivirotto,et al.  AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  Susan Lindquist,et al.  Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.

[108]  Samuel Bernard,et al.  Neurogenesis in the Striatum of the Adult Human Brain , 2014, Cell.

[109]  N. Boulis,et al.  Intramuscular administration of a VEGF zinc finger transcription factor activator (VEGF-ZFP-TF) improves functional outcomes in SOD1 rats , 2011, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[110]  Jeffry D. Sander,et al.  Efficient In Vivo Genome Editing Using RNA-Guided Nucleases , 2013, Nature Biotechnology.

[111]  D. Craufurd,et al.  Psychiatric disorders in preclinical Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[112]  Nazanin Mirzaei,et al.  Dose-dependent Neuroprotection of VEGF165 in Huntington's Disease Striatum. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[113]  Drew Endy,et al.  Measuring the activity of BioBrick promoters using an in vivo reference standard , 2009, Journal of biological engineering.

[114]  Pradeep J. Nathan,et al.  BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases , 2013, Nature Reviews Neuroscience.

[115]  J. Stelling,et al.  A tunable synthetic mammalian oscillator , 2009, Nature.

[116]  L. Shihabuddin,et al.  Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis , 2012, Neuron.